LIMINATUS PHARMA, INC. Fair Value Adjustment of Warrants
LIMINATUS PHARMA, INC. (LIMN) reported Fair Value Adjustment of Warrants of $29.25 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-14
- LIMINATUS PHARMA, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $29.25K, a 74.98% decline year-over-year.
- LIMINATUS PHARMA, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was $4.18K.
- LIMINATUS PHARMA, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$94.33K.
- LIMINATUS PHARMA, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$76.87K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.25K 10-Q · filed 2026-08-14 | $33.42K 10-Q · filed 2026-08-14 | -$60.91K derived: sum of 3 quarters · filed 2026-08-14 | -$137.78K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $4.18K S-1 · filed 2026-06-24 | -$90.16K derived: sum of 2 quarters · filed 2026-06-24 | -$167.03K derived: sum of 3 quarters · filed 2026-06-24 | -$50.13K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$94.33K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | -$171.21K derived: sum of 2 quarters · filed 2026-06-24 | -$54.31K derived: sum of 3 quarters · filed 2026-08-14 | -$54.31K S-1 · filed 2026-06-24 |
| 2025-09-30 | -$76.87K 10-Q · filed 2025-11-14 | $40.02K derived: sum of 2 quarters · filed 2026-08-14 | $40.02K 10-Q · filed 2025-11-14 | $40.02K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $116.89K 10-Q · filed 2026-08-14 | $116.89K 10-Q · filed 2026-08-14 | $116.89K derived: sum of 3 quarters · filed 2026-08-14 | $116.89K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 S-1 · filed 2026-06-24 | $0.00 derived: sum of 2 quarters · filed 2026-06-24 | $0.00 derived: sum of 3 quarters · filed 2026-06-24 | $0.00 derived: sum of 4 quarters · filed 2026-06-24 |
| 2024-12-31 | $0.00 derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $0.00 derived: sum of 2 quarters · filed 2026-06-24 | $0.00 derived: sum of 3 quarters · filed 2026-06-24 | $0.00 S-1 · filed 2026-06-24 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $0.00 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-10-06 | $0.00 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |